Literature DB >> 24893964

Amide coupling reaction for the synthesis of bispyridine-based ligands and their complexation to platinum as dinuclear anticancer agents.

Michael G Apps1, Ben W Johnson2, Oliver B Sutcliffe3, Sarah D Brown4, Nial J Wheate5.   

Abstract

Amide coupling reactions can be used to synthesize bispyridine-based ligands for use as bridging linkers in multinuclear platinum anticancer drugs. Isonicotinic acid, or its derivatives, are coupled to variable length diaminoalkane chains under an inert atmosphere in anhydrous DMF or DMSO with the use of a weak base, triethylamine, and a coupling agent, 1-propylphosphonic anhydride. The products precipitate from solution upon formation or can be precipitated by the addition of water. If desired, the ligands can be further purified by recrystallization from hot water. Dinuclear platinum complex synthesis using the bispyridine ligands is done in hot water using transplatin. The most informative of the chemical characterization techniques to determine the structure and gross purity of both the bispyridine ligands and the final platinum complexes is (1)H NMR with particular analysis of the aromatic region of the spectra (7-9 ppm). The platinum complexes have potential application as anticancer agents and the synthesis method can be modified to produce trinuclear and other multinuclear complexes with different hydrogen bonding functionality in the bridging ligand.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24893964      PMCID: PMC4208593          DOI: 10.3791/51740

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  19 in total

1.  Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile.

Authors:  Ga Young Park; Justin J Wilson; Ying Song; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

Review 2.  195Pt NMR--theory and application.

Authors:  Brett M Still; P G Anil Kumar; Janice R Aldrich-Wright; William S Price
Journal:  Chem Soc Rev       Date:  2006-11-17       Impact factor: 54.564

3.  The pain with platinum: oxaliplatin and neuropathy.

Authors:  Matthew C Kiernan
Journal:  Eur J Cancer       Date:  2007-10-30       Impact factor: 9.162

4.  Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).

Authors:  J Holford; F Raynaud; B A Murrer; K Grimaldi; J A Hartley; M Abrams; L R Kelland
Journal:  Anticancer Drug Des       Date:  1998-01

5.  Synthesis, cytotoxicity, cell uptake and DNA interstrand cross-linking of 4,4'-dipyrazolylmethane-linked multinuclear platinum anti-cancer complexes.

Authors:  N J Wheate; C Cullinane; L K Webster; J G Collins
Journal:  Anticancer Drug Des       Date:  2001 Apr-Jun

6.  Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.

Authors:  C Sessa; G Capri; L Gianni; F Peccatori; G Grasselli; J Bauer; M Zucchetti; L Viganò; A Gatti; C Minoia; P Liati; S Van den Bosch; A Bernareggi; G Camboni; S Marsoni
Journal:  Ann Oncol       Date:  2000-08       Impact factor: 32.976

7.  Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.

Authors:  Sarah D Brown; Katherine D Trotter; Oliver B Sutcliffe; Jane A Plumb; Bruce Waddell; Naomi E B Briggs; Nial J Wheate
Journal:  Dalton Trans       Date:  2012-08-10       Impact factor: 4.390

Review 8.  Review: ototoxic characteristics of platinum antitumor drugs.

Authors:  Dalian Ding; Brian L Allman; Richard Salvi
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

9.  Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.

Authors:  D I Jodrell; T R J Evans; W Steward; D Cameron; J Prendiville; C Aschele; C Noberasco; M Lind; J Carmichael; N Dobbs; G Camboni; B Gatti; F De Braud
Journal:  Eur J Cancer       Date:  2004-08       Impact factor: 9.162

10.  A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.

Authors:  Charlie Gourley; James Cassidy; Chris Edwards; Leslie Samuel; Donald Bisset; Gabriella Camboni; Anne Young; Dorothy Boyle; Duncan Jodrell
Journal:  Cancer Chemother Pharmacol       Date:  2003-11-07       Impact factor: 3.333

View more
  1 in total

1.  Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes.

Authors:  Ben W Johnson; Vincent Murray; Mark D Temple
Journal:  BMC Cancer       Date:  2016-05-25       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.